FMI’s New Report, titled, “Cell-Free Fetal DNA Testing Market: Global Industry Analysis and Opportunity Assessment 2016-2026” offers 10-year forecast and analysis.
Valley Cottage, NY -- (SBWIRE) -- 06/02/2016 -- Cell-free fetal DNA is an extension of prenatal testing in a safe and non-invasive method. Prenatal tests are used to find any irregularities in a fetus. The two predominant prenatal tests are chorionic villus sampling (CVS) and amniocentesis, both are invasive and could possess harm to the developing fetus, in some cases it can cause miscarriage. Cell-free fetal DNA is a new alternative of prenatal tests. Fetal DNA is found in mother's blood stream, cell-free fetal DNA enters into the blood stream through the placenta, placenta is a flattened organ in the uterus where maternal blood and fetal blood. The fetal DNA can be split into very acute fragments, less than 200 base pairs on an average. Maternal DNA fragments are also present in the blood.
Fetal DNA is first noticed after 22-25 days of fertilization and its concentrations increase as the time period of pregnancy increases. Diagnostic tests for pregnancy using fetal DNA is possible in seventh week of pregnancy. Fetal DNA can be rarely distinguished from the maternal DNA through diagnostic practice. Amniocentesis and chorionic villus sampling prenatal test is possible within 14-20 weeks and 10-13 weeks of pregnancy respectively. Cell-free fetal DNA non-invasive test is used to detect aneuploidy syndromes, fetal Down syndrome and signals a major shift in diagnostic practice and prenatal screening.
Cell-Free Fetal DNA Testing Market: Drivers and Restraints
The primary factor for the growth of global cell-free fetal DNA testing market is growing awareness in the people and requirement of safe or low risk obstetric procedures for prenatal testing. The technology which is used in cell-free DNA analysis and its application to prenatal screening for aneuploidy is rapidly changing. The growth of cell-free fetal DNA testing market is primarily attributed to accurate and effective results for aneuploidy screening. Major factor which limits the growth of the global cell-free fetal DNA testing market is high cost of cell-free fetal DNA tests.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1212
Cell-Free Fetal DNA Testing Market: Segmentation
Global cell-free fetal DNA testing market is classified on the basis of types of cell-free fetal DNA tests and geography
Based on test types, the global cell-free fetal DNA testing market is segmented into the following:
Detection of Abnormal Chromosome Number
Paternally Inherited Disorders
Cell-Free Fetal DNA Testing Market: Overview
The cell-free fetal DNA testing enables the parents to get information about general survivable fetal aneuploidies with a high accuracy and without any diagnostic procedure risk. In comparison with other screening method of aneuploidy, cell-free fetal DNA testing offers various advantages such as lower false-positive results of cell-free fetal DNA test as compared to other screening method. Aneuploidy is an unusual number of chromosome, typically characterized by the absence of one copy of a single chromosome or by the increase in the amount of chromosomes. The presence of an extra copy of chromosome 21 is called trisomy 21, which causes Down syndrome.
Cell-Free Fetal DNA Testing Market: Region-wise Outlook
The global cell-free fetal DNA testing market is expected to register a healthy CAGR for the forecast period. Depending on geographic region, global cell-free fetal DNA testing market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. North America held largest share in the global market of cell-free fetal DNA testing followed by Europe, Japan and Asia Pacific owing to high occurrence of several diseases and increasing number of aneuploidies, great advancement in field of aneuploidy screening and developed healthcare infrastructure. The developing nations in Asia Pacific, Middle East and Africa hold huge potential for growth in the global cell-free fetal DNA testing market, due to its quick and accurate result without any risk to developing fetus.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1212
Cell-Free Fetal DNA testing Market: Key Players
Some of the key participating global players in cell-free fetal DNA testing global market are Sequenom Laboratories, Illumina, Inc., Ariosa Diagnostics, Arup Laboratories, The Fetal Medicine Centre, Apollo Path labs.